At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
Potassium Nitrate (KNO3) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)
In Brief
A Phase 2 clinical trial evaluating Potassium Nitrate (KNO3) and Potassium Chloride (KCl) for Heart Failure. Completed, enrolled 84 participants across 3 sites.
Detailed Summary
This trial seeks to assess if potassium nitrate (KNO3) therapy improves exercise capacity and oxygen uptake in heart failure patients with preserved ejection fraction (HFpEF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
CollaboratorsNorthwestern University
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartAug 2016
Primary CompletionAug 2022
TodayJul 2026
First PostedJul 21, 2016
Enrollment StartAug 1, 2016
Primary CompletionAug 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 9.9 years ago
Interventions
Potassium Nitrate (KNO3)drug
The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
Potassium Chloride (KCl)drug
Potassium Chloride (KCl) is the matching placebo control drug in this trial.